Literature DB >> 19344576

Two-year outcome after Xpert stent implantation for treating below the knee lesions in critical limb ischemia.

Marc Bosiers1, Christos Lioupis, Koen Deloose, Jürgen Verbist, Patrick Peeters.   

Abstract

We investigated the efficacy of Xpert (Abbott Vascular, Abbott Park, IL) nitinol stents for the treatment of infrapopliteal lesions in patients with Critical Limb Ischemia (CLI). Between May 2005 and November 2007, 94 CLI patients (70 male, mean age 73.5 years) received 134 Xpert stents in 102 limbs. Seventy-nine patients (71.2%) were scored as Rutherford Category 4, 31 patients (27.9%) as Category 5 and 1 patient (0.9%) as Category 6. Primary endpoint of this study was defined as 2-year duplex derived primary patency. Secondary endpoints were 2-year limb salvage rate and the absence of reintervention after the index procedure. Kaplan Meier analysis reported 2-year primary patency and limb salvage rates of 54.4% and 90.8%, respectively. Stratification by lesion location did not reveal any significant differences in 2-year primary patency rates in proximal and distal below the knee lesions. Our results suggest that treatment with nitinol Xpert stents can be considered effective for treating CLI patients, with satisfying patency outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344576     DOI: 10.2310/6670.2009.00002

Source DB:  PubMed          Journal:  Vascular        ISSN: 1708-5381            Impact factor:   1.285


  3 in total

Review 1.  [Recanalization of the lower leg: PTA or stent?].

Authors:  S Müller-Hülsbeck
Journal:  Radiologe       Date:  2010-01       Impact factor: 0.635

2.  Endovascular reconstruction of popliteal and infrapopliteal arteries for limb salvage and wound healing in patients with critical limb ischemia - A retrospective analysis.

Authors:  Uday B Khanolkar; Biju Ephrem
Journal:  Indian Heart J       Date:  2016-01-18

Review 3.  [Current Strategy in Endovascular Management for Below-the-Knee Arterial Lesions].

Authors:  Kyosoo Hwang; Sang Woo Park
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.